Search Results
Search for other papers by Lars Bastholt in
Google Scholar
PubMed
Department of Nuclear Medicine, University Hospital Würzburg, Würzburg
Search for other papers by Michael C. Kreissl in
Google Scholar
PubMed
Search for other papers by Dagmar Führer in
Google Scholar
PubMed
Search for other papers by Ana L. Maia in
Google Scholar
PubMed
Search for other papers by Laura D. Locati in
Google Scholar
PubMed
Search for other papers by Léa Maciel in
Google Scholar
PubMed
Search for other papers by Yi Wu in
Google Scholar
PubMed
Search for other papers by Kevin N. Heller in
Google Scholar
PubMed
Search for other papers by Alan Webster in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Objectives: Effective management of adverse events (AEs) following vandetanib treatment is important to maximize clinical benefits. We examined whether more frequent contact with vandetanib-treated patients reduced AEs of CTCAE grade 2 or higher. Study Design: In this open-label, multicentre, phase III study, patients with locally advanced or metastatic medullary thyroid cancer were randomized to a patient outreach programme (outreach) or a standard AE monitoring schedule (vandetanib control) for 52 weeks. In addition to standard AE monitoring, patients in the outreach arm were contacted every 2 weeks by telephone/during their clinic visit for specific AE questioning related to diarrhoea, nausea, vomiting, fatigue, headache and rash. Patients received vandetanib at 200 or 300 mg/day, depending on the creatinine levels at screening. Results: Altogether, 205 patients were randomized (outreach, n = 103; vandetanib control, n = 102). This study did not meet its primary objective; the mean percentage of time patients experienced at least one AE of grade 2 or higher was higher for the outreach group (51.65%) than for the vandetanib control group (45.19%); the difference was not statistically significant (t statistic: 1.29; 95% CI -3.44 to 16.37%; p = 0.199). The most frequently reported AEs were diarrhoea (56.9% for the outreach group vs. 46.6% for the vandetanib controls), hypertension (36.3 vs. 31.1%), rash (25.5 vs. 24.3%) and nausea (25.5% vs. 18.4%), and the most frequently reported AEs of grade 2 or higher were hypertension (33.3 vs. 23.3%), diarrhoea (26.5 vs. 24.3%) and dermatitis acneiform (11.8 vs. 9.7%). Conclusions: Additional outreach to patients treated with vandetanib had no impact on the rate or severity of AEs compared to the standard AE monitoring schedule. AEs were consistent with the known safety profile of vandetanib.
